Absci Corporation
ABSI evidence brief
What we can confirm
- BioSniper Score:
- 6.8 / 10
- Market Cap:
- $1.41B
- Lead Asset:
- ABS-201 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ABSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABSI
Absci Corporation is a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics, with lead program ABS-201 in Phase 1 for androgenetic alopecia and endometriosis.
Key risk: Narrow pipeline dependency
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.41B
Cash Runway
—
Lead Asset
ABS-201 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Absci Corporation.
Absci Corporation is a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics, with lead program ABS-201 in Phase 1 for androgenetic alopecia and endometriosis.
- Cash & equivalents of $107.9M as of 2026-06-30 [sec].
- Total revenue of $0.3M and net income of -$33.2M for the quarter ended 2026-06-30 [sec].
- Completed a $100M underwritten offering including a $40M strategic investment from Eli Lilly & Company [news · published 2026-08-11].
- Lead program ABS-201 (anti-PRLR antibody) reported positive interim Phase 1 data from the HEADLINE trial [news · published 2026-08-11].
- Cash runway sufficient to fund operations into the second half of 2028 [news · published 2026-08-11].
What works
- AI-native platform (Origin-1) enables de novo antibody design against 'zero-prior' epitopes, opening targets like GPCRs and ion channels [sec · filed 2026-04-22].
- First two programs advanced from AI design to IND in ~2 years at ~$15M per program, compared to industry average of 4-6 years and >$50M [sec_mda · as of 2026-08-11].
- Positive interim Phase 1 data for ABS-201 in androgenetic alopecia, with solid PK/safety profile [news · published 2026-09-08].
- Strategic investment and development support from Eli Lilly extend cash runway into second half of 2028 [news · published 2026-08-11].
What to weigh
- Net loss widened to $33.2M for the quarter ended 2026-06-30, compared to a year ago [news · published 2026-08-12].
- Total revenue remains minimal at $0.3M, reflecting pre-commercial stage [sec].
- Reliance on a single lead program (ABS-201) for near-term catalysts; pipeline beyond ABS-201 and ABS-101 is early-stage [sec_mda · as of 2025-11-12].
- Significant ongoing R&D expenses with no guarantee of success in advancing discovery or platform adoption [sec_mda · as of 2025-08-12].
From the filings
Quoted directly from source documents.
Cash position and runway
“Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028”
News · August 11, 2026
Positive interim Phase 1 data for ABS-201
“Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201”
News · August 11, 2026
Capital-efficient development
“advanced our first two programs from AI design to IND (or foreign equivalent) in around 2 years with a total investment of approximately $15 million per program”
SEC MD&A · August 11, 2026
Risks & what to watch (4)›
Key risks
- Narrow pipeline dependency — Near-term catalysts hinge on ABS-201; other programs are early-stage [sec_mda · as of 2025-11-12].
- Widening net losses — Net loss of $33.2M in Q2 2026, wider than prior year [news · published 2026-08-12].
- Minimal revenue — Total revenue of only $0.3M as of 2026-06-30 [sec].
- R&D execution risk — Platform adoption and pipeline advancement require significant investment with uncertain success [sec_mda · as of 2025-08-12].
What to watch
- HEADLINE proof-of-concept readout for ABS-201 in androgenetic alopecia in H2 2026 [sec · filed 2026-04-22].
- Initiation of global Phase 2 trial for ABS-201 in endometriosis in Q4 2026 [sec · filed 2026-04-22].
- Potential proof-of-concept data for ABS-201 in endometriosis in H2 2027 [sec_mda · as of 2026-05-07].
- Continued development of Origin-1 against internal pipeline targets [sec · filed 2026-04-22].
Sources: News · SEC filings · SEC MD&A · Generated September 27, 2026 · How we verify sources →
Run Absci Corporation through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Absci Corporation facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.09 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
164
Total value held
$378.2M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 22,550,997 | $67.7M |
| ark investment management llc | 13,726,169 | $41.2M |
| blackrock, inc. | 11,255,194 | $33.8M |
| redmile group, llc | 8,253,316 | $24.8M |
| state street corp | 7,324,858 | $22.0M |
| vanguard capital management llc | 5,886,640 | $17.7M |
| advanced micro devices inc | 5,714,285 | $17.1M |
| geode capital management, llc | 3,343,068 | $10.0M |
| woodline partners lp | 3,300,169 | $9.9M |
| ameriprise financial inc | 3,180,141 | $9.5M |
Showing top 10 of 164 institutional holders of Absci Corporation. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 28.6%
- Days to cover
- 8.7
- Shares short
- 37,328,959
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABSI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Absci Corporation?
Absci Corporation is a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics, with lead program ABS-201 in Phase 1 for androgenetic alopecia and endometriosis.
What is Absci Corporation's lead drug candidate?
Absci Corporation's most advanced tracked candidate is ABS-201 (Phase 2) for endometriosis.
Who is the CEO of Absci Corporation?
Mr. Sean McClain is the chief executive officer of Absci Corporation (ABSI).
Where is Absci Corporation headquartered?
Absci Corporation (ABSI) is headquartered in Vancouver, WA, United States.
What therapeutic areas does Absci Corporation focus on?
Absci Corporation develops therapies across Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.